Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.

Yokota, Tomoya

Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. [electronic resource] - Anticancer research Oct 2011 - 3535-41 p. digital

Publication Type: Journal Article

1791-7530


Aged
Antineoplastic Agents--adverse effects
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Cisplatin--adverse effects
Disease-Free Survival
Docetaxel
Esophageal Neoplasms--drug therapy
Female
Fluorouracil--adverse effects
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Staging
Postoperative Complications--etiology
Recurrence
Retrospective Studies
Taxoids--adverse effects
Treatment Outcome